Nasdaq Moves to Delist Kyntra Bio; Company Seeks Hearing to Stay Suspension
KYNB is trading near its 52-week low of $5.62 (6.0% above the low).
Summary
Nasdaq formally determined to delist Kyntra Bio's stock after the company missed the September 29 compliance deadline. The company has requested a hearing, which stays the delisting while the Panel reviews the case.
Key Events · Legal and Risk Events · KYNB
-
Nasdaq Delisting Determination
On September 30, 2026, Nasdaq Staff determined to delist Kyntra Bio's common stock from the Nasdaq Global Select Market after the company failed to demonstrate compliance with Listing Rule 5450(b) by the September 29, 2026 deadline.
-
Hearing Request Stays Delisting
The company timely requested a hearing before a Nasdaq Hearings Panel, which stays the suspension and Form 25-NSE filing pending the Panel's written decision. The stock continues to trade under KYNB.
-
Potential 180-Day Extension
Under Listing Rule 5815(c)(1)(A), the Panel may grant an extension of up to 180 days from the Staff determination for the company to regain compliance, but there is no assurance the Panel will grant continued listing.
-
Prior Non-Compliance Notice
As previously disclosed on April 2, 2026, Nasdaq notified the company of non-compliance with Listing Rule 5450(b)(3)(A), which requires total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years.
Analysis · KYNB · Life Sciences
A formal delisting determination has been issued by Nasdaq after Kyntra Bio failed to satisfy continued listing requirements by the September 29, 2026 deadline. The company has requested a hearing before a Nasdaq Hearings Panel, which stays the delisting and allows the stock to continue trading under KYNB pending the Panel's decision. An extension of up to 180 days may be granted, but there is no assurance the Panel will allow continued listing. This is a critical governance and liquidity event: delisting would force the stock to trade on less liquid venues, potentially impairing shareholder value and access to capital.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYNB was trading at $5.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $5.62 to $12.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.